London
· Delayed Price · Currency is GBP · Price in CHF Basilea Pharmaceutica AG Statistics
Total Valuation
Basilea Pharmaceutica AG has a market cap or net worth of GBP 428.91 million. The enterprise value is 473.18 million.
| Market Cap | 428.91M |
| Enterprise Value | 473.18M |
Important Dates
The next estimated earnings date is Tuesday, February 18, 2025.
| Earnings Date | Feb 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -6.73% |
| Shares Change (QoQ) | +15.14% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 12.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 29.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -824.19 |
| EV / Sales | 3.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 57.56 |
Financial Position
The company has a current ratio of 4.10, with a Debt / Equity ratio of 6.70.
| Current Ratio | 4.10 |
| Quick Ratio | 2.96 |
| Debt / Equity | 6.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | 12.05 |
| Interest Coverage | -0.87 |
Financial Efficiency
Return on equity (ROE) is -4.10% and return on invested capital (ROIC) is -2.73%.
| Return on Equity (ROE) | -4.10% |
| Return on Assets (ROA) | -2.05% |
| Return on Capital (ROIC) | -2.73% |
| Revenue Per Employee | 841,171 |
| Profits Per Employee | -3,680 |
| Employee Count | 147 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 4.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.32% in the last 52 weeks. The beta is 0.74, so Basilea Pharmaceutica AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | +16.32% |
| 50-Day Moving Average | 41.22 |
| 200-Day Moving Average | 42.13 |
| Relative Strength Index (RSI) | 38.86 |
| Average Volume (20 Days) | 2,361 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Basilea Pharmaceutica AG had revenue of GBP 131.22 million and -574,124 in losses. Loss per share was -0.05.
| Revenue | 131.22M |
| Gross Profit | 21.24M |
| Operating Income | -6.04M |
| Pretax Income | -12.40M |
| Net Income | -574,124 |
| EBITDA | -4.93M |
| EBIT | -6.04M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 55.44 million in cash and 99.02 million in debt, giving a net cash position of -43.57 million.
| Cash & Cash Equivalents | 55.44M |
| Total Debt | 99.02M |
| Net Cash | -43.57M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 14.78M |
| Book Value Per Share | 1.22 |
| Working Capital | 103.23M |
Cash Flow
In the last 12 months, operating cash flow was 9.07 million and capital expenditures -850,620, giving a free cash flow of 8.22 million.
| Operating Cash Flow | 9.07M |
| Capital Expenditures | -850,620 |
| Free Cash Flow | 8.22M |
| FCF Per Share | n/a |
Margins
Gross margin is 16.19%, with operating and profit margins of -4.60% and -0.44%.
| Gross Margin | 16.19% |
| Operating Margin | -4.60% |
| Pretax Margin | -9.45% |
| Profit Margin | -0.44% |
| EBITDA Margin | -3.76% |
| EBIT Margin | -4.60% |
| FCF Margin | 6.26% |
Dividends & Yields
Basilea Pharmaceutica AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.73% |
| Shareholder Yield | 6.73% |
| Earnings Yield | -0.13% |
| FCF Yield | 1.92% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Basilea Pharmaceutica AG has an Altman Z-Score of -4.21. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.21 |
| Piotroski F-Score | n/a |